Purchase Order 75N90020P00542

<p>The NIH Clinical Center awarded a purchase order to Cellgenix USA for $17,112.96 on April 22, 2021, for GMP FLT-3L, GMP SCF, and GMP TPO reagents (50 micrograms each). Performance is scheduled in Germany with an ultimate completion date of April 30, 2021. The order is firm fixed price with no set-aside designation.</p>

<p>The NIH Clinical Center awarded a purchase order to Cellgenix USA for $11,942.50 on August 4, 2020, for CellGenix RH TPO GMP and preclinical grade materials and GMP FLT-3L (50 micrograms). The order is firm fixed price with no set-aside designation. Work is performed in Portsmouth, New Hampshire, with an ultimate completion date of August 11, 2020.</p>

<p>The NIH Clinical Center awarded a purchase order to Cellgenix USA for $26,780 on January 12, 2018, with completion by February 12, 2018. No set-aside applied. Performance occurs in Bethesda, Maryland. The order procures specialized pharmaceuticals for cell and gene therapy research, including cytokines, growth factors, and related reagents to support NIH research initiatives. The contract carries firm fixed-price pricing.</p>

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $103,103.00 firm fixed-price purchase order contract to Cellgenix USA, a division of Cellgenix GMBH, a for-profit manufacturer of goods. The contract, which had no set-aside designation, is for the provision of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, interleukin-4, and other cell therapy reagents to support federal cell and gene therapy research...

The National Institutes of Health (NIH) Clinical Center awarded a Firm Fixed Price Purchase Order contract worth $138,390.00 to Cellgenix USA, a division of Cellgenix GMBH. The contract is for the delivery of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, and interleukin-4 to support cell and gene therapy research and development at the NIH. Cellgenix USA has provided similar products to the NIH and the National Institute of Allergy and Infectious Diseases...

<p>The National Institutes of Health Clinical Center issued a purchase order to Cellgenix USA for $23,182.50 on February 5, 2020, for human interleukin 4 for use in NIH protocols. The order carries a firm fixed price and concludes on February 14, 2020. Place of performance is Portsmouth, New Hampshire.</p>

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. valued at $28,950.76 on March 24, 2020, with ultimate completion on April 24, 2020. Performance takes place in Bethesda, Maryland. The order is for advanced biological research products and laboratory supplies, including cell isolation kits, cell culture media, cell separation systems, and research-grade reagents to support biomedical research. No small business set-aside was used.</p>

The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. for $10,313.00 on September 6, 2017, with an ultimate completion date of September 5, 2018. No set-aside was used. Performance occurs at Bethesda, Maryland. The order is firm fixed-price and procures biological research products and laboratory supplies—including cell isolation kits, cell culture media, reagents, and specialized scientific equipment—to support biomedical research initiatives at the NIH Clinical...

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. valued at $28,950.76 on March 25, 2020, for advanced biological research products and laboratory supplies. Work is performed in Bethesda, Maryland. The order carried firm fixed-price pricing with an ultimate completion date of April 30, 2020. No set-aside was used.</p>

The National Institutes of Health Clinical Center awarded Stemcell Technologies Inc. a firm fixed-price purchase order valued at thirty-six thousand twenty-eight dollars and eighty cents ($36,028.80) to provide reagents and consumables. As the parent company, Stemcell Technologies will perform under the contract through its Kent, Washington facility from November 1st through December 1st, 2023. The Clinical Center, a component of the Department of Health and Human Services' National Institutes...